IL293076A - חלבונים כימריים של אופסין gpcr - Google Patents
חלבונים כימריים של אופסין gpcrInfo
- Publication number
- IL293076A IL293076A IL293076A IL29307622A IL293076A IL 293076 A IL293076 A IL 293076A IL 293076 A IL293076 A IL 293076A IL 29307622 A IL29307622 A IL 29307622A IL 293076 A IL293076 A IL 293076A
- Authority
- IL
- Israel
- Prior art keywords
- opsin
- seq
- gpcr
- chimeric
- nucleic acid
- Prior art date
Links
- 108050001704 Opsin Proteins 0.000 title claims description 647
- 102000010175 Opsin Human genes 0.000 title claims description 642
- 108090000623 proteins and genes Proteins 0.000 title claims description 84
- 102000004169 proteins and genes Human genes 0.000 title claims description 46
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 claims description 346
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 claims description 341
- 238000011144 upstream manufacturing Methods 0.000 claims description 180
- 150000007523 nucleic acids Chemical class 0.000 claims description 173
- 150000001413 amino acids Chemical class 0.000 claims description 140
- 102000039446 nucleic acids Human genes 0.000 claims description 135
- 108020004707 nucleic acids Proteins 0.000 claims description 135
- 102100038300 Metabotropic glutamate receptor 6 Human genes 0.000 claims description 122
- 108010038450 metabotropic glutamate receptor 6 Proteins 0.000 claims description 115
- 210000004027 cell Anatomy 0.000 claims description 109
- 210000000234 capsid Anatomy 0.000 claims description 100
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 97
- 230000026792 palmitoylation Effects 0.000 claims description 93
- 102100025912 Melanopsin Human genes 0.000 claims description 92
- 108010005417 melanopsin Proteins 0.000 claims description 87
- 239000013598 vector Substances 0.000 claims description 69
- 230000003834 intracellular effect Effects 0.000 claims description 56
- 108700019146 Transgenes Proteins 0.000 claims description 45
- 238000000034 method Methods 0.000 claims description 45
- 210000001743 on-bipolar cell Anatomy 0.000 claims description 39
- 108091006027 G proteins Proteins 0.000 claims description 37
- 102000030782 GTP binding Human genes 0.000 claims description 37
- 108091000058 GTP-Binding Proteins 0.000 claims description 37
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 36
- 230000004913 activation Effects 0.000 claims description 36
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 34
- 229920001184 polypeptide Polymers 0.000 claims description 32
- 210000004899 c-terminal region Anatomy 0.000 claims description 31
- NCYCYZXNIZJOKI-IOUUIBBYSA-N 11-cis-retinal Chemical compound O=C/C=C(\C)/C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-IOUUIBBYSA-N 0.000 claims description 30
- 102000004330 Rhodopsin Human genes 0.000 claims description 28
- 108090000820 Rhodopsin Proteins 0.000 claims description 28
- 108010003730 Cone Opsins Proteins 0.000 claims description 23
- 239000012634 fragment Substances 0.000 claims description 23
- 238000001415 gene therapy Methods 0.000 claims description 23
- 230000009261 transgenic effect Effects 0.000 claims description 21
- 101001086405 Bos taurus Rhodopsin Proteins 0.000 claims description 20
- 101000598987 Homo sapiens Medium-wave-sensitive opsin 1 Proteins 0.000 claims description 20
- 102100037812 Medium-wave-sensitive opsin 1 Human genes 0.000 claims description 20
- 108091008695 photoreceptors Proteins 0.000 claims description 18
- 101100122490 Drosophila melanogaster Galphaq gene Proteins 0.000 claims description 16
- 238000012546 transfer Methods 0.000 claims description 16
- 241001465754 Metazoa Species 0.000 claims description 15
- 238000010353 genetic engineering Methods 0.000 claims description 15
- 101710159027 Parapinopsin Proteins 0.000 claims description 13
- 102000005962 receptors Human genes 0.000 claims description 13
- 108020003175 receptors Proteins 0.000 claims description 13
- 230000002207 retinal effect Effects 0.000 claims description 13
- 230000026731 phosphorylation Effects 0.000 claims description 12
- 238000006366 phosphorylation reaction Methods 0.000 claims description 12
- 238000006467 substitution reaction Methods 0.000 claims description 12
- 241001164825 Adeno-associated virus - 8 Species 0.000 claims description 11
- 201000004569 Blindness Diseases 0.000 claims description 11
- 208000007014 Retinitis pigmentosa Diseases 0.000 claims description 11
- 238000012217 deletion Methods 0.000 claims description 11
- 230000037430 deletion Effects 0.000 claims description 11
- 239000003814 drug Substances 0.000 claims description 11
- 230000004438 eyesight Effects 0.000 claims description 11
- 239000002245 particle Substances 0.000 claims description 11
- 108090000565 Capsid Proteins Proteins 0.000 claims description 10
- 102100023321 Ceruloplasmin Human genes 0.000 claims description 10
- 241000242583 Scyphozoa Species 0.000 claims description 10
- 241000702421 Dependoparvovirus Species 0.000 claims description 9
- 108091006047 fluorescent proteins Proteins 0.000 claims description 9
- 102000034287 fluorescent proteins Human genes 0.000 claims description 9
- 108020001507 fusion proteins Proteins 0.000 claims description 9
- 102000037865 fusion proteins Human genes 0.000 claims description 9
- 241000356457 Salticidae Species 0.000 claims description 8
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims description 8
- 239000004473 Threonine Substances 0.000 claims description 8
- 230000007850 degeneration Effects 0.000 claims description 8
- 238000003780 insertion Methods 0.000 claims description 8
- 230000037431 insertion Effects 0.000 claims description 8
- 230000008172 membrane trafficking Effects 0.000 claims description 8
- 102100039126 5-hydroxytryptamine receptor 7 Human genes 0.000 claims description 7
- 101710150237 5-hydroxytryptamine receptor 7 Proteins 0.000 claims description 7
- 238000002864 sequence alignment Methods 0.000 claims description 7
- 238000010453 CRISPR/Cas method Methods 0.000 claims description 6
- 102100040890 Glucagon receptor Human genes 0.000 claims description 6
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims description 6
- 238000013160 medical therapy Methods 0.000 claims description 6
- 230000035772 mutation Effects 0.000 claims description 6
- 239000002105 nanoparticle Substances 0.000 claims description 6
- 239000002773 nucleotide Substances 0.000 claims description 6
- 125000003729 nucleotide group Chemical group 0.000 claims description 6
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims description 6
- 108020001612 μ-opioid receptors Proteins 0.000 claims description 6
- 101001137074 Homo sapiens Long-wave-sensitive opsin 1 Proteins 0.000 claims description 5
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims description 5
- 102100035576 Long-wave-sensitive opsin 1 Human genes 0.000 claims description 5
- 108010010914 Metabotropic glutamate receptors Proteins 0.000 claims description 5
- 102000016193 Metabotropic glutamate receptors Human genes 0.000 claims description 5
- 102000012740 beta Adrenergic Receptors Human genes 0.000 claims description 5
- 108010079452 beta Adrenergic Receptors Proteins 0.000 claims description 5
- 210000001116 retinal neuron Anatomy 0.000 claims description 5
- 102000040125 5-hydroxytryptamine receptor family Human genes 0.000 claims description 4
- 108091032151 5-hydroxytryptamine receptor family Proteins 0.000 claims description 4
- 239000013607 AAV vector Substances 0.000 claims description 4
- 101150047684 Gabbr2 gene Proteins 0.000 claims description 4
- 101000944277 Homo sapiens Inward rectifier potassium channel 2 Proteins 0.000 claims description 4
- 101001120990 Homo sapiens Short-wave-sensitive opsin 1 Proteins 0.000 claims description 4
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims description 4
- 108010065028 Metabotropic Glutamate 5 Receptor Proteins 0.000 claims description 4
- 102100038357 Metabotropic glutamate receptor 5 Human genes 0.000 claims description 4
- 102100025909 Opsin-3 Human genes 0.000 claims description 4
- 102100032646 Opsin-5 Human genes 0.000 claims description 4
- 102100026557 Short-wave-sensitive opsin 1 Human genes 0.000 claims description 4
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims description 4
- 230000001419 dependent effect Effects 0.000 claims description 4
- 239000013604 expression vector Substances 0.000 claims description 4
- 210000004602 germ cell Anatomy 0.000 claims description 4
- 210000003292 kidney cell Anatomy 0.000 claims description 4
- 208000002780 macular degeneration Diseases 0.000 claims description 4
- 239000011859 microparticle Substances 0.000 claims description 4
- 102000051367 mu Opioid Receptors Human genes 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims description 4
- 239000004474 valine Substances 0.000 claims description 4
- 108010063919 Glucagon Receptors Proteins 0.000 claims description 3
- 101001040075 Homo sapiens Glucagon receptor Proteins 0.000 claims description 3
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 claims description 3
- 239000010931 gold Substances 0.000 claims description 3
- 229910052737 gold Inorganic materials 0.000 claims description 3
- 230000003054 hormonal effect Effects 0.000 claims description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 3
- 210000003660 reticulum Anatomy 0.000 claims description 3
- 241001655883 Adeno-associated virus - 1 Species 0.000 claims description 2
- 241000202702 Adeno-associated virus - 3 Species 0.000 claims description 2
- 241000580270 Adeno-associated virus - 4 Species 0.000 claims description 2
- 241001634120 Adeno-associated virus - 5 Species 0.000 claims description 2
- 241000972680 Adeno-associated virus - 6 Species 0.000 claims description 2
- 241001164823 Adeno-associated virus - 7 Species 0.000 claims description 2
- 241000649045 Adeno-associated virus 10 Species 0.000 claims description 2
- 241000649046 Adeno-associated virus 11 Species 0.000 claims description 2
- 241000649047 Adeno-associated virus 12 Species 0.000 claims description 2
- 102100034159 Beta-3 adrenergic receptor Human genes 0.000 claims description 2
- 101000720966 Homo sapiens Opsin-3 Proteins 0.000 claims description 2
- 101001086282 Homo sapiens Opsin-5 Proteins 0.000 claims description 2
- 102100033114 Inward rectifier potassium channel 2 Human genes 0.000 claims description 2
- 101710176225 Kallikrein-8 Proteins 0.000 claims description 2
- 101710130961 Opsin-3 Proteins 0.000 claims description 2
- 101710131039 Opsin-5 Proteins 0.000 claims description 2
- 102000014992 beta1-adrenergic receptor activity proteins Human genes 0.000 claims description 2
- 108040006808 beta1-adrenergic receptor activity proteins Proteins 0.000 claims description 2
- 102000014974 beta2-adrenergic receptor activity proteins Human genes 0.000 claims description 2
- 108040006828 beta2-adrenergic receptor activity proteins Proteins 0.000 claims description 2
- 108040005346 beta3-adrenergic receptor activity proteins Proteins 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 102220032988 rs281865408 Human genes 0.000 claims description 2
- 210000000130 stem cell Anatomy 0.000 claims description 2
- 238000011830 transgenic mouse model Methods 0.000 claims description 2
- 108091006116 chimeric peptides Proteins 0.000 claims 2
- 235000001014 amino acid Nutrition 0.000 description 130
- 229940024606 amino acid Drugs 0.000 description 95
- 125000003275 alpha amino acid group Chemical group 0.000 description 73
- 235000018102 proteins Nutrition 0.000 description 35
- 230000004044 response Effects 0.000 description 31
- 241000702423 Adeno-associated virus - 2 Species 0.000 description 30
- 230000019491 signal transduction Effects 0.000 description 23
- 241001529936 Murinae Species 0.000 description 21
- 125000000539 amino acid group Chemical group 0.000 description 21
- 239000002299 complementary DNA Substances 0.000 description 16
- 210000001525 retina Anatomy 0.000 description 16
- 101800001415 Bri23 peptide Proteins 0.000 description 15
- 102400000107 C-terminal peptide Human genes 0.000 description 15
- 101800000655 C-terminal peptide Proteins 0.000 description 15
- 241000699670 Mus sp. Species 0.000 description 15
- 238000010276 construction Methods 0.000 description 15
- 102000034354 Gi proteins Human genes 0.000 description 12
- 108091006101 Gi proteins Proteins 0.000 description 12
- 230000000694 effects Effects 0.000 description 12
- 230000032258 transport Effects 0.000 description 12
- 102100039174 Rod cGMP-specific 3',5'-cyclic phosphodiesterase subunit beta Human genes 0.000 description 11
- 238000007792 addition Methods 0.000 description 10
- 108091006044 chimera Proteins 0.000 description 10
- 230000008878 coupling Effects 0.000 description 10
- 238000010168 coupling process Methods 0.000 description 10
- 238000005859 coupling reaction Methods 0.000 description 10
- 230000001225 therapeutic effect Effects 0.000 description 9
- 108010029485 Protein Isoforms Proteins 0.000 description 8
- 102000001708 Protein Isoforms Human genes 0.000 description 8
- 210000000170 cell membrane Anatomy 0.000 description 8
- 238000013461 design Methods 0.000 description 8
- 230000014509 gene expression Effects 0.000 description 8
- 101001032837 Homo sapiens Metabotropic glutamate receptor 6 Proteins 0.000 description 7
- 241000699666 Mus <mouse, genus> Species 0.000 description 7
- 102000036646 Signalosomes Human genes 0.000 description 7
- 108091007411 Signalosomes Proteins 0.000 description 7
- 230000004927 fusion Effects 0.000 description 7
- 230000002068 genetic effect Effects 0.000 description 7
- 208000018769 loss of vision Diseases 0.000 description 7
- 231100000864 loss of vision Toxicity 0.000 description 7
- 239000012528 membrane Substances 0.000 description 7
- 230000004393 visual impairment Effects 0.000 description 7
- 230000003993 interaction Effects 0.000 description 6
- 210000002569 neuron Anatomy 0.000 description 6
- 239000013612 plasmid Substances 0.000 description 6
- 210000003994 retinal ganglion cell Anatomy 0.000 description 6
- 230000000638 stimulation Effects 0.000 description 6
- 101710197658 Capsid protein VP1 Proteins 0.000 description 5
- 241000242741 Cubozoa Species 0.000 description 5
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 5
- 239000002262 Schiff base Substances 0.000 description 5
- 150000004753 Schiff bases Chemical class 0.000 description 5
- 238000003556 assay Methods 0.000 description 5
- 230000000052 comparative effect Effects 0.000 description 5
- 230000001086 cytosolic effect Effects 0.000 description 5
- 210000001787 dendrite Anatomy 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 230000002349 favourable effect Effects 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 230000010189 intracellular transport Effects 0.000 description 5
- 239000003446 ligand Substances 0.000 description 5
- 230000004298 light response Effects 0.000 description 5
- 210000000608 photoreceptor cell Anatomy 0.000 description 5
- 230000011664 signaling Effects 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- NCYCYZXNIZJOKI-HPNHMNAASA-N 11Z-retinal Natural products CC(=C/C=O)C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-HPNHMNAASA-N 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 208000003098 Ganglion Cysts Diseases 0.000 description 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- 108020005004 Guide RNA Proteins 0.000 description 4
- 101000720986 Homo sapiens Melanopsin Proteins 0.000 description 4
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 4
- 239000004472 Lysine Substances 0.000 description 4
- 101000720987 Mus musculus Melanopsin Proteins 0.000 description 4
- 101710118046 RNA-directed RNA polymerase Proteins 0.000 description 4
- 208000005400 Synovial Cyst Diseases 0.000 description 4
- 235000004279 alanine Nutrition 0.000 description 4
- 108091036078 conserved sequence Proteins 0.000 description 4
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 4
- 235000018417 cysteine Nutrition 0.000 description 4
- 229940088598 enzyme Drugs 0.000 description 4
- 230000001747 exhibiting effect Effects 0.000 description 4
- 230000004807 localization Effects 0.000 description 4
- 230000001404 mediated effect Effects 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 230000037361 pathway Effects 0.000 description 4
- 230000006461 physiological response Effects 0.000 description 4
- 230000000717 retained effect Effects 0.000 description 4
- 238000001890 transfection Methods 0.000 description 4
- 230000000007 visual effect Effects 0.000 description 4
- 239000004475 Arginine Substances 0.000 description 3
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 3
- 108091006146 Channels Proteins 0.000 description 3
- 102000034353 G alpha subunit Human genes 0.000 description 3
- 108091006099 G alpha subunit Proteins 0.000 description 3
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 3
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 3
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 3
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 3
- 206010034960 Photophobia Diseases 0.000 description 3
- 201000007737 Retinal degeneration Diseases 0.000 description 3
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 3
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 3
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 3
- 235000009582 asparagine Nutrition 0.000 description 3
- 229960001230 asparagine Drugs 0.000 description 3
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 239000003623 enhancer Substances 0.000 description 3
- 238000010304 firing Methods 0.000 description 3
- 238000010362 genome editing Methods 0.000 description 3
- WHUUTDBJXJRKMK-VKHMYHEASA-L glutamate group Chemical group N[C@@H](CCC(=O)[O-])C(=O)[O-] WHUUTDBJXJRKMK-VKHMYHEASA-L 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 208000013469 light sensitivity Diseases 0.000 description 3
- 238000004806 packaging method and process Methods 0.000 description 3
- 210000003569 retinal bipolar cell Anatomy 0.000 description 3
- 230000004258 retinal degeneration Effects 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 230000007704 transition Effects 0.000 description 3
- 230000004304 visual acuity Effects 0.000 description 3
- 102000003916 Arrestin Human genes 0.000 description 2
- 108090000328 Arrestin Proteins 0.000 description 2
- 230000005724 C-terminal phosphorylation Effects 0.000 description 2
- 108091033409 CRISPR Proteins 0.000 description 2
- 238000010356 CRISPR-Cas9 genome editing Methods 0.000 description 2
- OHCQJHSOBUTRHG-KGGHGJDLSA-N FORSKOLIN Chemical compound O=C([C@@]12O)C[C@](C)(C=C)O[C@]1(C)[C@@H](OC(=O)C)[C@@H](O)[C@@H]1[C@]2(C)[C@@H](O)CCC1(C)C OHCQJHSOBUTRHG-KGGHGJDLSA-N 0.000 description 2
- 102000034355 G beta-gamma complex Human genes 0.000 description 2
- 108091006102 G beta-gamma complex Proteins 0.000 description 2
- 102100033063 G protein-activated inward rectifier potassium channel 1 Human genes 0.000 description 2
- 108010008959 G-Protein-Coupled Receptor Kinases Proteins 0.000 description 2
- 102000006575 G-Protein-Coupled Receptor Kinases Human genes 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- 101000944266 Homo sapiens G protein-activated inward rectifier potassium channel 1 Proteins 0.000 description 2
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 2
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 2
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 2
- 108010047357 Luminescent Proteins Proteins 0.000 description 2
- 102000006830 Luminescent Proteins Human genes 0.000 description 2
- YHIPILPTUVMWQT-UHFFFAOYSA-N Oplophorus luciferin Chemical compound C1=CC(O)=CC=C1CC(C(N1C=C(N2)C=3C=CC(O)=CC=3)=O)=NC1=C2CC1=CC=CC=C1 YHIPILPTUVMWQT-UHFFFAOYSA-N 0.000 description 2
- 102000004257 Potassium Channel Human genes 0.000 description 2
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 230000036982 action potential Effects 0.000 description 2
- 239000004191 allura red AC Substances 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- -1 arginine (R ) Chemical class 0.000 description 2
- 230000006399 behavior Effects 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 238000005415 bioluminescence Methods 0.000 description 2
- 230000029918 bioluminescence Effects 0.000 description 2
- 239000007975 buffered saline Substances 0.000 description 2
- 210000004900 c-terminal fragment Anatomy 0.000 description 2
- 239000001639 calcium acetate Substances 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 230000008632 circadian clock Effects 0.000 description 2
- 210000000805 cytoplasm Anatomy 0.000 description 2
- 238000000586 desensitisation Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 2
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 2
- 229930195712 glutamate Natural products 0.000 description 2
- 210000004326 gyrus cinguli Anatomy 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 2
- 238000005286 illumination Methods 0.000 description 2
- 238000000126 in silico method Methods 0.000 description 2
- 238000012623 in vivo measurement Methods 0.000 description 2
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 2
- 229960000310 isoleucine Drugs 0.000 description 2
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 238000001000 micrograph Methods 0.000 description 2
- 230000003278 mimic effect Effects 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 238000009126 molecular therapy Methods 0.000 description 2
- 238000001668 nucleic acid synthesis Methods 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 239000008177 pharmaceutical agent Substances 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- BZQFBWGGLXLEPQ-REOHCLBHSA-N phosphoserine Chemical compound OC(=O)[C@@H](N)COP(O)(O)=O BZQFBWGGLXLEPQ-REOHCLBHSA-N 0.000 description 2
- 230000035790 physiological processes and functions Effects 0.000 description 2
- 108020001213 potassium channel Proteins 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 210000002763 pyramidal cell Anatomy 0.000 description 2
- 239000013608 rAAV vector Substances 0.000 description 2
- 239000013646 rAAV2 vector Substances 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 125000006850 spacer group Chemical group 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 230000000087 stabilizing effect Effects 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 230000004960 subcellular localization Effects 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 238000010361 transduction Methods 0.000 description 2
- 230000026683 transduction Effects 0.000 description 2
- 238000013519 translation Methods 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- DDOQBQRIEWHWBT-VKHMYHEASA-N (2S)-2-amino-4-phosphonobutanoic acid Chemical compound OC(=O)[C@@H](N)CCP(O)(O)=O DDOQBQRIEWHWBT-VKHMYHEASA-N 0.000 description 1
- 208000002267 Anti-neutrophil cytoplasmic antibody-associated vasculitis Diseases 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 241000239290 Araneae Species 0.000 description 1
- 108050003620 Arrestin-C Proteins 0.000 description 1
- 102100026440 Arrestin-C Human genes 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 238000011740 C57BL/6 mouse Methods 0.000 description 1
- 102100033868 Cannabinoid receptor 1 Human genes 0.000 description 1
- 101710187010 Cannabinoid receptor 1 Proteins 0.000 description 1
- 101150044789 Cap gene Proteins 0.000 description 1
- 108091005462 Cation channels Proteins 0.000 description 1
- 238000001353 Chip-sequencing Methods 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- SUZLHDUTVMZSEV-UHFFFAOYSA-N Deoxycoleonol Natural products C12C(=O)CC(C)(C=C)OC2(C)C(OC(=O)C)C(O)C2C1(C)C(O)CCC2(C)C SUZLHDUTVMZSEV-UHFFFAOYSA-N 0.000 description 1
- 108091008898 G protein-coupled receptors class A orphans Proteins 0.000 description 1
- 108700028146 Genetic Enhancer Elements Proteins 0.000 description 1
- 108010027915 Glutamate Receptors Proteins 0.000 description 1
- 102000018899 Glutamate Receptors Human genes 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 101001137060 Homo sapiens Oligophrenin-1 Proteins 0.000 description 1
- 101000829506 Homo sapiens Rhodopsin kinase GRK1 Proteins 0.000 description 1
- 101000844510 Homo sapiens Transient receptor potential cation channel subfamily M member 1 Proteins 0.000 description 1
- 108090000862 Ion Channels Proteins 0.000 description 1
- 102000004310 Ion Channels Human genes 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- 241000405718 Lethenteron camtschaticum Species 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 108060001084 Luciferase Proteins 0.000 description 1
- 239000005089 Luciferase Substances 0.000 description 1
- 102300060141 Melanopsin isoform 1 Human genes 0.000 description 1
- 101000744209 Mus musculus 5-hydroxytryptamine receptor 7 Proteins 0.000 description 1
- 101100259948 Mus musculus Tbata gene Proteins 0.000 description 1
- 102100035592 Oligophrenin-1 Human genes 0.000 description 1
- 102000003840 Opioid Receptors Human genes 0.000 description 1
- 108090000137 Opioid Receptors Proteins 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- 108090000526 Papain Proteins 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 108700008625 Reporter Genes Proteins 0.000 description 1
- 102100023742 Rhodopsin kinase GRK1 Human genes 0.000 description 1
- 102000005801 Rod Opsins Human genes 0.000 description 1
- 108010005063 Rod Opsins Proteins 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 108091081024 Start codon Proteins 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 108091027544 Subgenomic mRNA Proteins 0.000 description 1
- 102000003617 TRPM1 Human genes 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 101150024766 VP1 gene Proteins 0.000 description 1
- 101710096684 Vertebrate ancient opsin Proteins 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 241001492404 Woodchuck hepatitis virus Species 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 102000030621 adenylate cyclase Human genes 0.000 description 1
- 108060000200 adenylate cyclase Proteins 0.000 description 1
- 206010064930 age-related macular degeneration Diseases 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 101150010487 are gene Proteins 0.000 description 1
- 238000013528 artificial neural network Methods 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 210000003050 axon Anatomy 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 238000002306 biochemical method Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000003855 cell nucleus Anatomy 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000001886 ciliary effect Effects 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 230000004186 co-expression Effects 0.000 description 1
- OHCQJHSOBUTRHG-UHFFFAOYSA-N colforsin Natural products OC12C(=O)CC(C)(C=C)OC1(C)C(OC(=O)C)C(O)C1C2(C)C(O)CCC1(C)C OHCQJHSOBUTRHG-UHFFFAOYSA-N 0.000 description 1
- 230000004456 color vision Effects 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 230000001054 cortical effect Effects 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 210000000172 cytosol Anatomy 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000001152 differential interference contrast microscopy Methods 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000005014 ectopic expression Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000007159 enucleation Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 239000004403 ethyl p-hydroxybenzoate Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000007306 functionalization reaction Methods 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000012215 gene cloning Methods 0.000 description 1
- 238000001476 gene delivery Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 230000005283 ground state Effects 0.000 description 1
- 230000004886 head movement Effects 0.000 description 1
- 102000034345 heterotrimeric G proteins Human genes 0.000 description 1
- 108091006093 heterotrimeric G proteins Proteins 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 125000001165 hydrophobic group Chemical group 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 230000031146 intracellular signal transduction Effects 0.000 description 1
- 230000031700 light absorption Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 238000004020 luminiscence type Methods 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 230000009456 molecular mechanism Effects 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 201000006938 muscular dystrophy Diseases 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- 210000005157 neural retina Anatomy 0.000 description 1
- 208000004296 neuralgia Diseases 0.000 description 1
- 230000004007 neuromodulation Effects 0.000 description 1
- 208000021722 neuropathic pain Diseases 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 230000004466 optokinetic reflex Effects 0.000 description 1
- 239000004306 orthophenyl phenol Substances 0.000 description 1
- 229940055729 papain Drugs 0.000 description 1
- 235000019834 papain Nutrition 0.000 description 1
- 230000002186 photoactivation Effects 0.000 description 1
- 238000007699 photoisomerization reaction Methods 0.000 description 1
- 230000016732 phototransduction Effects 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 230000007180 physiological regulation Effects 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000001124 posttranscriptional effect Effects 0.000 description 1
- 239000004297 potassium metabisulphite Substances 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000026447 protein localization Effects 0.000 description 1
- 230000029983 protein stabilization Effects 0.000 description 1
- 238000000455 protein structure prediction Methods 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 239000013647 rAAV8 vector Substances 0.000 description 1
- 239000000018 receptor agonist Substances 0.000 description 1
- 229940044601 receptor agonist Drugs 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 108010054624 red fluorescent protein Proteins 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 230000021907 regulation of circadian rhythm Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004243 retinal function Effects 0.000 description 1
- 210000003583 retinal pigment epithelium Anatomy 0.000 description 1
- 210000002508 rod bipolar cell Anatomy 0.000 description 1
- 230000002295 serotoninergic effect Effects 0.000 description 1
- 238000007493 shaping process Methods 0.000 description 1
- 230000008054 signal transmission Effects 0.000 description 1
- 230000007781 signaling event Effects 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 239000004402 sodium ethyl p-hydroxybenzoate Substances 0.000 description 1
- 239000001540 sodium lactate Substances 0.000 description 1
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Substances [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 230000000392 somatic effect Effects 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000004173 sunset yellow FCF Substances 0.000 description 1
- 230000000153 supplemental effect Effects 0.000 description 1
- 230000008093 supporting effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 230000007306 turnover Effects 0.000 description 1
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
- 230000004382 visual function Effects 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
- 210000004127 vitreous body Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
- C07K14/723—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH receptor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
- A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
- A61K48/0033—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid the non-active part being non-polymeric
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
- A61K48/0066—Manipulation of the nucleic acid to modify its expression pattern, e.g. enhance its duration of expression, achieved by the presence of particular introns in the delivered nucleic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5403—IL-3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/545—IL-1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/55—IL-2
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/60—Fusion polypeptide containing spectroscopic/fluorescent detection, e.g. green fluorescent protein [GFP]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/007—Vector systems having a special element relevant for transcription cell cycle specific enhancer/promoter combination
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Toxicology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Biotechnology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Ophthalmology & Optometry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Cell Biology (AREA)
- Endocrinology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Virology (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CH15092019 | 2019-11-29 | ||
| PCT/EP2020/083960 WO2021105509A1 (en) | 2019-11-29 | 2020-11-30 | Chimeric opsin gpcr proteins |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL293076A true IL293076A (he) | 2022-07-01 |
Family
ID=73726778
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL293076A IL293076A (he) | 2019-11-29 | 2020-11-30 | חלבונים כימריים של אופסין gpcr |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US20240174743A1 (he) |
| EP (1) | EP4065153A1 (he) |
| JP (1) | JP2023504136A (he) |
| KR (1) | KR20220111294A (he) |
| CN (1) | CN115038458A (he) |
| AU (2) | AU2020392702B2 (he) |
| BR (1) | BR112022010095A2 (he) |
| CA (1) | CA3162568A1 (he) |
| CL (1) | CL2022001376A1 (he) |
| CO (1) | CO2022008784A2 (he) |
| CR (1) | CR20220283A (he) |
| EC (1) | ECSP22050231A (he) |
| IL (1) | IL293076A (he) |
| JO (1) | JOP20220128A1 (he) |
| MX (1) | MX2022006496A (he) |
| PE (1) | PE20230093A1 (he) |
| WO (1) | WO2021105509A1 (he) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023116720A1 (en) * | 2021-12-20 | 2023-06-29 | National Institute Of Biological Sciences, Beijing | ULTRA LIGHT-SENSITIVE NEUROPSIN-BASED OPTOGENETIC TOOL FOR ACTIVATING G q-COUPLED SIGNALING AND/OR ACTIVATING CELLS |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL2723767T3 (pl) | 2011-06-24 | 2016-06-30 | Haag Streit Medtech Ag | Światłoczułe chimerowe białko GPCR |
-
2020
- 2020-11-30 CA CA3162568A patent/CA3162568A1/en active Pending
- 2020-11-30 BR BR112022010095A patent/BR112022010095A2/pt unknown
- 2020-11-30 MX MX2022006496A patent/MX2022006496A/es unknown
- 2020-11-30 EP EP20820068.3A patent/EP4065153A1/en active Pending
- 2020-11-30 US US17/756,547 patent/US20240174743A1/en active Pending
- 2020-11-30 IL IL293076A patent/IL293076A/he unknown
- 2020-11-30 AU AU2020392702A patent/AU2020392702B2/en active Active
- 2020-11-30 JO JOP/2022/0128A patent/JOP20220128A1/ar unknown
- 2020-11-30 JP JP2022532030A patent/JP2023504136A/ja active Pending
- 2020-11-30 CR CR20220283A patent/CR20220283A/es unknown
- 2020-11-30 WO PCT/EP2020/083960 patent/WO2021105509A1/en active Application Filing
- 2020-11-30 CN CN202080081599.XA patent/CN115038458A/zh active Pending
- 2020-11-30 KR KR1020227021853A patent/KR20220111294A/ko active Search and Examination
- 2020-11-30 PE PE2022000865A patent/PE20230093A1/es unknown
-
2022
- 2022-05-25 CL CL2022001376A patent/CL2022001376A1/es unknown
- 2022-06-24 EC ECSENADI202250231A patent/ECSP22050231A/es unknown
- 2022-06-24 CO CONC2022/0008784A patent/CO2022008784A2/es unknown
-
2023
- 2023-10-06 AU AU2023241362A patent/AU2023241362A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CL2022001376A1 (es) | 2023-03-24 |
| AU2020392702A1 (en) | 2022-07-21 |
| BR112022010095A2 (pt) | 2022-09-06 |
| KR20220111294A (ko) | 2022-08-09 |
| CR20220283A (es) | 2022-09-30 |
| JOP20220128A1 (ar) | 2023-01-30 |
| US20240174743A1 (en) | 2024-05-30 |
| AU2020392702B2 (en) | 2023-07-06 |
| ECSP22050231A (es) | 2022-08-31 |
| CN115038458A (zh) | 2022-09-09 |
| CO2022008784A2 (es) | 2022-09-20 |
| AU2023241362A1 (en) | 2023-10-26 |
| EP4065153A1 (en) | 2022-10-05 |
| MX2022006496A (es) | 2022-09-07 |
| PE20230093A1 (es) | 2023-01-16 |
| WO2021105509A1 (en) | 2021-06-03 |
| CA3162568A1 (en) | 2021-06-03 |
| JP2023504136A (ja) | 2023-02-01 |
| AU2020392702A9 (en) | 2022-12-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2018247199A1 (en) | Devices, systems and methods for optogenetic modulation of action potentials in target cells | |
| ES2920850T3 (es) | Procedimientos y composiciones para el tratamiento de enfermedades oculares genéticas | |
| KR102008538B1 (ko) | 감광성 키메라 gpcr 단백질 | |
| US8470790B2 (en) | Restoration of visual responses by in vivo delivery of rhodopsin nucleic acids | |
| US9453241B2 (en) | AAV-mediated subcellular targeting of heterologous rhodopsins in retinal ganglion cells | |
| ES2819123T3 (es) | Proteínas del factor VIII que tienen secuencias ancestrales, vectores de expresión, y usos relacionados con ellos | |
| CA2919995A1 (en) | Recombinant aav-crumbs homologue composition and methods for treating lca-8 and progressive rp | |
| CN114126665A (zh) | 眼底黄色斑点症(abca4)的基因疗法 | |
| JP2023058505A (ja) | 光応答性タンパク質及びその利用 | |
| AU2020392702B2 (en) | Chimeric opsin GPCR proteins | |
| US20210403518A1 (en) | Bistable type ii opsins and uses thereof | |
| CN114729009A (zh) | 用于眼部基因递送的aav载体变体 | |
| US8734780B2 (en) | Methods for treating cardiac pacing conditions |